Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05490719
PHASE2

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Sponsor: Tianjin Medical University Cancer Institute and Hospital

View on ClinicalTrials.gov

Summary

This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial(IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Official title: A Single Arm, Phase II Clinical Study of Chemoradiationtherapy Combined With QL1706 (Anti-CTLA-4 and PD-1 Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

39

Start Date

2022-08-01

Completion Date

2025-09

Last Updated

2024-05-21

Healthy Volunteers

No

Interventions

DRUG

QL1706

QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.

Locations (1)

Tianjin cancer hospital

Tianjin, Tianjin Municipality, China